A simple clinical score to promote and enhance ferroportin disease screening.

Abstract

BACKGROUND & AIMS:

Ferroportin disease is a rare genetic iron overload disorder which may be underdiagnosed, with recent data suggesting it occurs at a higher prevalence than suspected. Costs and the lack of defined criteria to prompt genetic testing preclude large-scale molecular screening. Hence, we aimed to develop a readily available scoring system to promote and enhance ferroportin disease screening.

METHODS:

Our derivation cohort included probands tested for ferroportin disease from 2008 to 2016 in our rare disease network. Data were prospectively recorded. Univariate and multivariate logistic regression were used to determine significant criteria, and odds ratios were used to build a weighted score. A cut-off value was defined using a ROC curve with a predefined aim of 90% sensitivity. An independent cohort was used for cross validation.

RESULTS:

Our derivation cohort included 1,306 patients. Mean age was 55±14 years, ferritin 1,351±1,357 μg/L, and liver iron concentration (LIC) 166±77 μmol/g. Pathogenic variants (n = 32) were identified in 71 patients. In multivariate analysis: female sex, younger age, higher ferritin, higher LIC and the absence of hypertension or diabetes were significantly associated with the diagnosis of ferroportin disease (AUROC in whole derivation cohort 0.83 [0.78-0.88]). The weighted score was based on sex, age, the presence of hypertension or diabetes, ferritin level and LIC. An AUROC of 0.83 (0.77-0.88) was obtained in the derivation cohort without missing values. Using 9.5 as a cut-off, sensitivity was 93.6 (91.7-98.3) %, specificity 49.5 (45.5-53.6) %, positive likelihood ratio 1.8 (1.6-2.0) and negative likelihood ratio 0.17 (0.04-0.37).

CONCLUSION:

We describe a readily available score with simple criteria and good diagnostic performance that could be used to screen patients for ferroportin disease in routine clinical practice.

LAY SUMMARY:

Increased iron burden associated with metabolic syndrome is a very common condition. Ferroportin disease is a dominant genetic iron overload disorder whose prevalence is higher than initially thought. They can be difficult to distinguish from each other, but the limited availability of genetic testing and the lack of definitive guidelines prevent adequate screening. We herein describe a simple and definitive clinical score to help clinicians decide whether to perform genetic testing.

• Authors: Amandine Landemaine, Houda Hamdi-Roze, Séverine Cunat, Véronique Loustaud-Ratti, Xavier Causse, Si Nafa Si Ahmed, Bernard Drénou, Christophe Bureau, Gilles Pelletier, Caroline De Kerguenec, Nathalie Ganne-Carrie, Stéphane Durupt, Fabrice Laine, Olivier Loréal, Martine Ropert, Lenaick Detivaud, Jeff Morcet, Patricia Aguilar-Martinez, Yves M Deugnier, Edouard Bardou-Jacquet
• Journal: Journal of hepatology (J Hepatol) Vol. 76 Issue 3 Pg. 568-576 (03 2022) ISSN: 1600-0641 [Electronic] Netherlands
• PMID: 34748893 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Chemical References

• Cation Transport Proteins
• metal transporting protein 1
• Iron

Topics

• Aged
• Cation Transport Proteins (analysis, blood)
• Cohort Studies
• Female
• Hemochromatosis (blood, diagnosis)
• Humans
• Iron (metabolism)
• Iron Overload (blood, complications)
• Logistic Models
• Male
• Mass Screening (methods, statistics & numerical data)
• Middle Aged
• ROC Curve
• Research Design (standards, statistics & numerical data)